Howard Financial Services LTD. Sells 382 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Mar 23rd, 2023

Howard Financial Services LTD. lessened its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 12.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,609 shares of the company’s stock after selling 382 shares during the period. Howard Financial Services LTD.’s holdings in Johnson & Johnson were worth $461,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lincoln Capital Corp grew its position in shares of Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after acquiring an additional 183 shares during the period. Ieq Capital LLC grew its position in shares of Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after acquiring an additional 6,154 shares during the period. RFG Advisory LLC boosted its holdings in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares during the period. FDx Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 0.3% during the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after buying an additional 153 shares during the period. Finally, HM Payson & Co. boosted its holdings in shares of Johnson & Johnson by 3.2% during the 3rd quarter. HM Payson & Co. now owns 783,538 shares of the company’s stock worth $127,999,000 after buying an additional 24,188 shares during the period. Institutional investors own 67.94% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on JNJ shares. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Guggenheim assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Finally, Atlantic Securities lifted their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $151.05 on Thursday. The firm has a 50 day moving average of $160.63 and a 200-day moving average of $167.70. The stock has a market capitalization of $393.38 billion, a PE ratio of 22.41, a PEG ratio of 2.63 and a beta of 0.54. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 12 month low of $150.71 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.13 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.99%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.